Entropy Technologies LP Acquires Shares of 2,332 HealthEquity, Inc. (NASDAQ:HQY)

Entropy Technologies LP bought a new position in shares of HealthEquity, Inc. (NASDAQ:HQY) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 2,332 shares of the company’s stock, valued at approximately $224,000.

Several other hedge funds have also modified their holdings of HQY. Choreo LLC raised its position in HealthEquity by 7.2% in the fourth quarter. Choreo LLC now owns 22,879 shares of the company’s stock worth $2,204,000 after acquiring an additional 1,533 shares in the last quarter. GDS Wealth Management increased its holdings in shares of HealthEquity by 43.6% in the 4th quarter. GDS Wealth Management now owns 41,131 shares of the company’s stock valued at $3,947,000 after purchasing an additional 12,493 shares in the last quarter. Greenleaf Trust acquired a new stake in shares of HealthEquity in the fourth quarter valued at about $214,000. KBC Group NV boosted its holdings in HealthEquity by 56.7% during the fourth quarter. KBC Group NV now owns 3,860 shares of the company’s stock worth $370,000 after buying an additional 1,397 shares in the last quarter. Finally, Curated Wealth Partners LLC acquired a new position in HealthEquity during the fourth quarter worth about $242,000. 99.55% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Robert W. Selander sold 5,750 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $111.29, for a total value of $639,917.50. Following the transaction, the director now directly owns 78,219 shares of the company’s stock, valued at approximately $8,704,992.51. This trade represents a 6.85 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Stuart B. Parker sold 25,000 shares of the business’s stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $96.72, for a total value of $2,418,000.00. Following the sale, the director now directly owns 19,061 shares of the company’s stock, valued at approximately $1,843,579.92. This trade represents a 56.74 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 39,000 shares of company stock valued at $3,895,788. Insiders own 2.20% of the company’s stock.

HealthEquity Trading Down 0.5 %

Shares of HQY opened at $113.94 on Friday. HealthEquity, Inc. has a fifty-two week low of $65.01 and a fifty-two week high of $115.59. The company has a market capitalization of $9.87 billion, a PE ratio of 104.53, a price-to-earnings-growth ratio of 1.61 and a beta of 0.55. The stock has a fifty day moving average of $101.90 and a two-hundred day moving average of $90.53. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.20 and a current ratio of 3.20.

HealthEquity (NASDAQ:HQY) last released its earnings results on Monday, December 9th. The company reported $0.59 earnings per share for the quarter, missing the consensus estimate of $0.71 by ($0.12). HealthEquity had a return on equity of 9.70% and a net margin of 8.41%. During the same period in the previous year, the company earned $0.40 EPS. As a group, analysts forecast that HealthEquity, Inc. will post 2.32 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Royal Bank of Canada boosted their price target on HealthEquity from $100.00 to $105.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 10th. Mizuho assumed coverage on HealthEquity in a report on Wednesday, December 4th. They issued an “outperform” rating and a $126.00 target price on the stock. The Goldman Sachs Group initiated coverage on HealthEquity in a research note on Friday, November 15th. They set a “neutral” rating and a $108.00 price target for the company. JMP Securities increased their price objective on shares of HealthEquity from $105.00 to $107.00 and gave the company a “market outperform” rating in a research note on Tuesday, December 10th. Finally, BTIG Research lifted their target price on shares of HealthEquity from $110.00 to $130.00 and gave the stock a “buy” rating in a research report on Thursday, November 14th. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $110.71.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.